Despite the limitations of this study, our results provide a critical understanding of the effects of anti–PD-L1 and anti-CD73 combination in the treatment of EGFR-mutated NSCLC, which could have important implications for continued clinical development of this combination therapy. This evidence concerns the gene NT5E and non-small cell lung carcinoma.